Variants at chromosome 20 (ASIP locus) and melanoma risk

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 42-54

  MacCioni, Livia ^a   Rachakonda, P Sivaramakrishna ^a   Scherer, Dominique ^a   Bermejo, Justo Lorenzo ^b   Planelles, Dolores ^c   Requena, Celia ^d   Hemminki, Kari ^a,e   Nagore, Eduardo ^d,f   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Center for Blood Transfusion   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

ASIP; melanoma; polymorphisms

Indexed keywords

AGOUTI PROTEIN; MELANOCORTIN 1 RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; ASIP GENE; CANCER RISK; CHILD; CHROMOSOMAL LOCALIZATION; CHROMOSOME 20; CONTROLLED STUDY; FEMALE; GENE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MC1R GENE; MELANOMA SKIN CANCER; NCOA6 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGOUTI SIGNALING PROTEIN; CASE-CONTROL STUDIES; CHILD; CHROMOSOMES, HUMAN, PAIR 20; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NUCLEAR RECEPTOR COACTIVATORS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MELANOCORTIN, TYPE 1; YOUNG ADULT;

EID: 84868207507     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27648     Document Type: Article

References (50)

1. Chin L, Garraway LA, Fisher DE,. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20: 2149-82.
2. Ibrahim N, Haluska FG,. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4: 551-79.
3. Berwick M, Wiggins C,. The current epidemiology of cutaneous malignant melanoma. Front Biosci 2006; 11: 1244-54.
4. MacKie RM, Hauschild A, Eggermont AM,. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (suppl 6): vi1-7.
5. Veierod MB, Adami HO, Lund E, et al. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010; 19: 111-20.
6. Olsen CM, Carroll HJ, Whiteman DC,. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer 2010; 127: 2430-45.
7. Bloethner S, Scherer D, Drechsel M, et al. Malignant melanomaa-a genetic overview. Actas Dermosifiliogr 2009; 100 (suppl 1): 38-51.
8. Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40: 886-91.
9. Brown KM, Macgregor S, Montgomery GW, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008; 40: 838-40.
10. Nan H, Kraft P, Hunter DJ, et al. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009; 125: 909-17.
11. Falchi M, Bataille V, Hayward NK, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009; 41: 915-9.
12. Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41: 920-5.
13. Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130: 520-8.
14. Macgregor S, Montgomery GW, Liu JZ, et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011; 43: 1114-8.
15. Barrett JH, Iles MM, Harland M, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011; 43: 1108-13.
16. Amos CI, Wang LE, Lee JE, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011; 20: 5012-23.
17. Lin JY, Fisher DE,. Melanocyte biology and skin pigmentation. Nature 2007; 445: 843-50.
18. Scherer D, Nagore E, Bermejo JL, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009; 125: 1868-75.
19. Scherer D, Kumar R,. Genetics of pigmentation in skin cancera-a review. Mutat Res 2010; 705: 141-53.
20. Sulem P, Gudbjartsson DF, Stacey SN, et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008; 40: 835-7.
21. Lin W, Qureshi AA, Kraft P, et al. ASIP genetic variants and the number of non-melanoma skin cancers. Cancer Causes Control 2011; 22: 495-501.
22. Helsing P, Nymoen DA, Rootwelt H, et al. MC1R, ASIP, TYR, and TYRP1 gene variants in a population-based series of multiple primary melanomas. Genes Chromosomes Cancer 2012; 51: 654-61.
23. Voisey J, van Daal A,. Agouti: from mouse to man, from skin to fat. Pigment Cell Res 2002; 15: 10-8.
24. Voisey J, Kelly G, Van Daal A,. Agouti signal protein regulation in human melanoma cells. Pigment Cell Res 2003; 16: 65-71.
25. Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97: 998-1007.
26. Kanetsky PA, Swoyer J, Panossian S, et al. A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet 2002; 70: 770-5.
27. Bonilla C, Boxill LA, Donald SA, et al. The 8818G allele of the agouti signaling protein (ASIP) gene is ancestral and is associated with darker skin color in African Americans. Hum Genet 2005; 116: 402-6.
28. Brudnik U, Branicki W, Wojas-Pelc A, et al. The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. Exp Dermatol 2009; 18: 167-74.
29. Nagore E, Botella-Estrada R, Requena C, et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site. Actas Dermosifiliogr 2009; 100: 205-11.
30. Nagore E, Botella-Estrada R, Garcia-Casado Z, et al. Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain. J Eur Acad Dermatol Venereol 2008; 22: 931-6.
31. Nagore E, Pereda C, Botella-Estrada R, et al. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control 2009; 20: 115-9.
32. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
33. Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011; 103: 1227-35.
34. Visser M, Kayser M, Palstra RJ,. HERC2 rs12913832 modulates human pigmentation by attenuating chromatin loop formation between a long-range enhancer and the OCA2 promoter. Genome Res 2012; 22: 446-55.
35. Tuupanen S, Turunen M, Lehtonen R, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41: 885-90.
36. Lee SK, Anzick SL, Choi JE, et al. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 1999; 274: 34283-93.
37. Lee SK, Na SY, Jung SY, et al. Activating protein-1, nuclear factor-kappaB, and serum response factor as novel target molecules of the cancer-amplified transcription coactivator ASC-2. Mol Endocrinol 2000; 14: 915-25.
38. Kuang SQ, Liao L, Zhang H, et al. Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality. J Biol Chem 2002; 277: 45356-60.
39. Kong HJ, Yu HJ, Hong S, et al. Interaction and functional cooperation of the cancer-amplified transcriptional coactivator activating signal cointegrator-2 and E2F-1 in cell proliferation. Mol Cancer Res 2003; 1: 948-58.
40. Mahajan MA, Samuels HH,. Nuclear receptor coactivator/coregulator NCoA6(NRC) is a pleiotropic coregulator involved in transcription, cell survival, growth and development. Nucl Recept Signal 2008; 6: e002.
41. Lee J, Kim DH, Lee S, et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA 2009; 106: 8513-8.
42. Kim DH, Lee J, Lee B, et al. ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Mol Endocrinol 2009; 23: 1556-62.
43. Zhang H, Liao L, Kuang SQ, et al. Spatial distribution of the messenger ribonucleic acid and protein of the nuclear receptor coactivator, amplified in breast cancer-3, in mice. Endocrinology 2003; 144: 1435-43.
44. Guo Z, Linn JF, Wu G, et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med 2004; 10: 374-81.
45. Potthoff MJ, Olson EN,. MEF2: a central regulator of diverse developmental programs. Development 2007; 134: 4131-40.
46. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-53.
47. Manolio TA,. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363: 166-76.
48. Harismendy O, Notani D, Song X, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 2011; 470: 264-8.
49. Cookson W, Liang L, Abecasis G, et al. Mapping complex disease traits with global gene expression. Nat Rev Genet 2009; 10: 184-94.
50. Nicolae DL, Gamazon E, Zhang W, et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010; 6: e1000888.